Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148615569> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2148615569 endingPage "1410" @default.
- W2148615569 startingPage "1407" @default.
- W2148615569 abstract "The aim of this study was to evaluate the efficacy of the combination of epirubicin, cisplatin and ralitrexed (Tomudex). ECT, in patients with advanced oesophageal or gastric adenocarcinoma. Efficacy was assessed primarily as response rate and secondarily in terms of toxicity, time to progression and survival.Twenty-one patients with histologically and/or cytologically proven unresectable (7) or metastatic (14) gastro-oesophageal adenocarcinoma, who had bi-dimensionally measurable disease, with ECOG performance status < or = 2. with adequate haematological, hepatic and renal function received first-line chemotherapy with epirubicin (50 mg/m2). cisplatin (60 mg/m2) and Tomudex (2.5 mg/m2), ECT, at three-weekly intervals. Treatment consisted of three cycles of chemotherapy, with a further three cycles if there was disease response or stabilisation.ECT is an active regimen in the treatment of advanced gastro-oesophageal adenocarcinoma with an overall intention-to-treat response rate of 29% (95% confidence intervals (CI): 11%-52%). In addition, 4 (19%) patients had stable disease. Median time to progression was 19 weeks (95% CI: 7-31 weeks). Median overall survival was 18 weeks (95% CI: 11-24 weeks). Seventeen patients failed to complete the six cycles of treatment due to disease progression (5). toxicity (3), non-toxic death (1 pulmonary embolism, 1 cardiac), severe allergy to epirubicin (1), patient decision (1) and five patients after the study was discontinued early due to toxicity. There were three toxic deaths: two due to sepsis complicating neutropaenia and one due to cardiorespiratory failure following drug induced enteritis. Nine patients experienced grade 3 or 4 neutropaenia, two patients experienced grade 3 or 4 nausea and vomiting and one patient had grade 4 diarrhoea.The combination of epirubicin, cisplatin and tomudex is active against advanced gastro-oesophageal adenocarcinoma but the toxicity suggests that further evaluation in a randomised comparison to ECF is not appropriate." @default.
- W2148615569 created "2016-06-24" @default.
- W2148615569 creator A5014220064 @default.
- W2148615569 creator A5017543761 @default.
- W2148615569 creator A5034457278 @default.
- W2148615569 creator A5035699979 @default.
- W2148615569 creator A5037221378 @default.
- W2148615569 creator A5049940232 @default.
- W2148615569 creator A5051127654 @default.
- W2148615569 creator A5079633934 @default.
- W2148615569 creator A5083569681 @default.
- W2148615569 creator A5085230100 @default.
- W2148615569 creator A5023341878 @default.
- W2148615569 date "2001-10-01" @default.
- W2148615569 modified "2023-10-18" @default.
- W2148615569 title "A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma" @default.
- W2148615569 cites W1843791750 @default.
- W2148615569 cites W1910458543 @default.
- W2148615569 cites W1964540194 @default.
- W2148615569 cites W1976651872 @default.
- W2148615569 cites W1994069365 @default.
- W2148615569 cites W2017874057 @default.
- W2148615569 cites W2055406451 @default.
- W2148615569 cites W2064296430 @default.
- W2148615569 cites W2065574327 @default.
- W2148615569 cites W2085643819 @default.
- W2148615569 cites W2111513457 @default.
- W2148615569 doi "https://doi.org/10.1023/a:1012552823543" @default.
- W2148615569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11762812" @default.
- W2148615569 hasPublicationYear "2001" @default.
- W2148615569 type Work @default.
- W2148615569 sameAs 2148615569 @default.
- W2148615569 citedByCount "19" @default.
- W2148615569 countsByYear W21486155692012 @default.
- W2148615569 countsByYear W21486155692013 @default.
- W2148615569 countsByYear W21486155692015 @default.
- W2148615569 countsByYear W21486155692019 @default.
- W2148615569 countsByYear W21486155692020 @default.
- W2148615569 countsByYear W21486155692022 @default.
- W2148615569 crossrefType "journal-article" @default.
- W2148615569 hasAuthorship W2148615569A5014220064 @default.
- W2148615569 hasAuthorship W2148615569A5017543761 @default.
- W2148615569 hasAuthorship W2148615569A5023341878 @default.
- W2148615569 hasAuthorship W2148615569A5034457278 @default.
- W2148615569 hasAuthorship W2148615569A5035699979 @default.
- W2148615569 hasAuthorship W2148615569A5037221378 @default.
- W2148615569 hasAuthorship W2148615569A5049940232 @default.
- W2148615569 hasAuthorship W2148615569A5051127654 @default.
- W2148615569 hasAuthorship W2148615569A5079633934 @default.
- W2148615569 hasAuthorship W2148615569A5083569681 @default.
- W2148615569 hasAuthorship W2148615569A5085230100 @default.
- W2148615569 hasBestOaLocation W21486155691 @default.
- W2148615569 hasConcept C126322002 @default.
- W2148615569 hasConcept C141071460 @default.
- W2148615569 hasConcept C2776694085 @default.
- W2148615569 hasConcept C2776755627 @default.
- W2148615569 hasConcept C2778822529 @default.
- W2148615569 hasConcept C2780835546 @default.
- W2148615569 hasConcept C2781413609 @default.
- W2148615569 hasConcept C71924100 @default.
- W2148615569 hasConcept C90924648 @default.
- W2148615569 hasConceptScore W2148615569C126322002 @default.
- W2148615569 hasConceptScore W2148615569C141071460 @default.
- W2148615569 hasConceptScore W2148615569C2776694085 @default.
- W2148615569 hasConceptScore W2148615569C2776755627 @default.
- W2148615569 hasConceptScore W2148615569C2778822529 @default.
- W2148615569 hasConceptScore W2148615569C2780835546 @default.
- W2148615569 hasConceptScore W2148615569C2781413609 @default.
- W2148615569 hasConceptScore W2148615569C71924100 @default.
- W2148615569 hasConceptScore W2148615569C90924648 @default.
- W2148615569 hasIssue "10" @default.
- W2148615569 hasLocation W21486155691 @default.
- W2148615569 hasLocation W21486155692 @default.
- W2148615569 hasOpenAccess W2148615569 @default.
- W2148615569 hasPrimaryLocation W21486155691 @default.
- W2148615569 hasRelatedWork W1884490053 @default.
- W2148615569 hasRelatedWork W2023888239 @default.
- W2148615569 hasRelatedWork W2106642332 @default.
- W2148615569 hasRelatedWork W2358269044 @default.
- W2148615569 hasRelatedWork W2377624260 @default.
- W2148615569 hasRelatedWork W2401483455 @default.
- W2148615569 hasRelatedWork W2405533122 @default.
- W2148615569 hasRelatedWork W2411082724 @default.
- W2148615569 hasRelatedWork W2415928550 @default.
- W2148615569 hasRelatedWork W2418599011 @default.
- W2148615569 hasVolume "12" @default.
- W2148615569 isParatext "false" @default.
- W2148615569 isRetracted "false" @default.
- W2148615569 magId "2148615569" @default.
- W2148615569 workType "article" @default.